Dominguez-Mozo MI, Galán V, Ramió-Torrentà L, Quiroga A, Quintana E, Villar LM, Costa-Frossard L, Fernández-Velasco JI, Villarrubia N, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R
A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.
Muñoz-San Martín M, Gómez I, Quiroga-Varela A, Gonzalez-Del Río M, Robles Cedeño R, Álvarez G, Buxó M, Miguela A, Villar LM, Castillo-Villalba J, Casanova B, Quintana E, Ramió-Torrentà L
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis
Coll-Martinez C, Quintana E, Buxó M, Salavedra-Pont J, Gasull-Vicens L, Quiroga-Varela A, Costa-Frossard L, Villar LM, Fernández-Díaz E, Gracia J, Aladro Y, Méndez-Burgos A, Cerezo M, Ramió-Torrentà L, Gich J
Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis.
Picón C, Tejeda-Velarde A, Fernández-Velasco JI, Comabella M, Álvarez-Lafuente R, Quintana E, Sainz de la Maza S, Monreal E, Villarrubia N, Álvarez-Cermeño JC, Domínguez-Mozo MI, Ramió-Torrentà L, Rodríguez-Martín E, Roldán E, Aladro Y, Medina S, Espiño M, Masjuan J, Matute-Blanch C, Muñoz-San Martín M, Espejo C, Guaza C, Muriel A, Costa-Frossard L, Villar LM
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis
Coll-Martinez C, Quintana E, Salavedra-Pont J, Buxó M, González-Del-Rio M, Gómez I, Muñoz-San Martín M, Villar LM, Álvarez-Bravo G, Robles-Cedeño R, Ramió-Torrentà L, Gich J
Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis
Walo-Delgado PE, Monreal E, Medina S, Quintana E, Sainz de la Maza S, Fernández-Velasco JI, Lapuente P, Comabella M, Ramió-Torrentà L, Montalban X, Midaglia L, Villarrubia N, Carrasco-Sayalero A, Rodríguez-Martín E, Roldán E, Meca-Lallana J, Alvarez-Lafuente R, Masjuan J, Costa-Frossard L, Villar LM
Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
Aliaga-Gaspar P, Hurtado-Guerrero I, Ciano-Petersen NL, Urbaneja P, Brichette-Mieg I, Reyes V, Rodriguez-Bada JL, Alvarez-Lafuente R, Arroyo R, Quintana E, Ramió-Torrentà L, Alonso A, Leyva L, Fernández O, Oliver-Martos B
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment
